**NIH-CAP 2007-08 Participating Companies**

+---------------------------------+------------------------------------+
| **Acoustic MedSystems, Inc.**   | Everette C. Burdette               |
|                                 |                                    |
| Champaign, IL                   | Tel: 217-239-0900                  |
|                                 |                                    |
| Industry Sector: Medical        | Email: clifb@acousticmed.com       |
| Devices                         |                                    |
+---------------------------------+------------------------------------+
| Acoustic MedSystems, Inc. (AMS) |                                    |
| focuses on the development of   |                                    |
| minimally invasive              |                                    |
| interventional methods for      |                                    |
| treatment, treatment guidance,  |                                    |
| and delivery monitoring. These  |                                    |
| are predominately real-time     |                                    |
| methods for imaging, image      |                                    |
| processing and therapy delivery |                                    |
| guidance. Included are its      |                                    |
| proprietary ACOUSTXTM           |                                    |
| technology (Applicators with    |                                    |
| Controllable Output of          |                                    |
| Ultrasound for Selective        |                                    |
| Treatment) for minimally        |                                    |
| invasive targeted thermal       |                                    |
| ablation of tumors and other    |                                    |
| soft-tissue diseases and its    |                                    |
| spatially-registered image      |                                    |
| guidance methodologies for      |                                    |
| treatment delivery and          |                                    |
| monitoring. The ACOUSTX         |                                    |
| technology can provide          |                                    |
| significant benefits and        |                                    |
| improvements over traditional   |                                    |
| surgical procedures, as well as |                                    |
| over other minimally invasive   |                                    |
| thermal technologies, and has   |                                    |
| treatment potential for a wide  |                                    |
| range of soft-tissues           |                                    |
| (malignant and benign tumors,   |                                    |
| other soft tissue disorders)    |                                    |
| including breast, liver,        |                                    |
| uterus, prostate, brain, lung,  |                                    |
| bladder, and colo-rectal        |                                    |
| diseases. Additionally, the     |                                    |
| technology can be effective for |                                    |
| the treatment of prostate BPH,  |                                    |
| uterine fibroids, and stress    |                                    |
| urinary incontinence. The other |                                    |
| core technologies of the        |                                    |
| company are in image            |                                    |
| registration and real-time      |                                    |
| intraoperative treatment        |                                    |
| guidance and monitoring.        |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Advanced Brain Monitoring,    | Mandy Sinning                      |
| Inc.**                          |                                    |
|                                 | Tel: 760-720-0099                  |
| Carlsbad, CA                    |                                    |
|                                 | Email: msinning@b-alert.com        |
| Industry Sector: Medical        |                                    |
| Devices                         |                                    |
+---------------------------------+------------------------------------+
| Advanced Brain Monitoring, Inc. |                                    |
| (ABM) is the first company to   |                                    |
| address sleep apnea, memory     |                                    |
| dysfunction, and alertness      |                                    |
| monitoring with instrument      |                                    |
| systems that combine laboratory |                                    |
| level accuracy with the         |                                    |
| portability, ease of use and    |                                    |
| low cost of consumer            |                                    |
| electronics. Patients with      |                                    |
| conditions targeted by ABM's    |                                    |
| products total over 110 million |                                    |
| people in the US alone, and the |                                    |
| vast majority have not been     |                                    |
| assisted diagnostically. ABM    |                                    |
| systems make widespread use by  |                                    |
| physicians, dentists,           |                                    |
| industrial/transportation       |                                    |
| companies, and consumers        |                                    |
| possible.                       |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Advanced Circulatory Systems, | Mike Black                         |
| Inc.**                          |                                    |
|                                 | Tel: 952-947-9551                  |
| Eden Prairie, MN                |                                    |
|                                 | Email:                             |
| Industry Sector: Medical        | mblack@advancedcirculatory.com     |
| Devices                         |                                    |
+---------------------------------+------------------------------------+
| Advanced Circulatory Systems is |                                    |
| focused on developing and       |                                    |
| commercializing a sudden        |                                    |
| cardiac arrest resuscitation    |                                    |
| system. The platform for this   |                                    |
| system is a combination of      |                                    |
| proprietary technologies        |                                    |
| developed by Advanced           |                                    |
| Circulatory Systems to increase |                                    |
| blood flow during CPR and       |                                    |
| survival rates for cardiac      |                                    |
| arrest victims. The goal is to  |                                    |
| create a cost-effective         |                                    |
| treatment system through an     |                                    |
| optimized integration of        |                                    |
| multiple cardiac arrest-related |                                    |
| technologies that will          |                                    |
| significantly improve cardiac   |                                    |
| arrest survival rates.          |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **AfaSci, Inc.**                | Xinmin Simon Xie                   |
|                                 |                                    |
| Carlsbad, CA                    | Tel: 650-784-5658                  |
|                                 |                                    |
| Industry Sector:                | Email: simonxie@afasci.com         |
| Pharmaceuticals                 |                                    |
+---------------------------------+------------------------------------+
| AfaSci, Inc. currently develops |                                    |
| a wireless, non-invasive rodent |                                    |
| homecage monitoring system for  |                                    |
| in vivo high-throughput         |                                    |
| screening (HTS) of drug         |                                    |
| efficacy and safety, and for    |                                    |
| behavioral phenotyping of       |                                    |
| transgenic and knockout mice,   |                                    |
| through collaborations with     |                                    |
| Pennsylvania State University,  |                                    |
| Pennsylvania, The George        |                                    |
| Washington University,          |                                    |
| Washington, D.C.), and research |                                    |
| institutions (SRI               |                                    |
| International, CA). We provide  |                                    |
| products and services in these  |                                    |
| areas.                          |                                    |
|                                 |                                    |
| In the future direction, we     |                                    |
| will explore contract services  |                                    |
| on in vivo drug screening and   |                                    |
| potentially new drug discovery  |                                    |
| via commercial contracts,       |                                    |
| collaborations and/or partner   |                                    |
| with both biotech or            |                                    |
| pharmaceuticals.                |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **AJ Medical Devices, Inc**     | Robert Arzbaecher                  |
|                                 |                                    |
| Wilmette, IL                    | Tel: 847-251-5020                  |
|                                 |                                    |
| Industry Sector: Medical        | Email: arzbaecher@iit.edu          |
| Devices                         |                                    |
+---------------------------------+------------------------------------+
| AJ Medical Devices develops     |                                    |
| monitoring systems for the      |                                    |
| high-risk patient that are      |                                    |
| based on small sensors          |                                    |
| implanted under the skin that   |                                    |
| communicate externally via      |                                    |
| wireless. The first product,    |                                    |
| CardioAlarm, has an implanted   |                                    |
| sensor that records a patient's |                                    |
| EKG, automatically detects an   |                                    |
| abnormal heart rhythm, and      |                                    |
| transmits an alarm and EKG      |                                    |
| recording to a 24/7 patient     |                                    |
| monitoring service, without the |                                    |
| encumbrance of electrodes on    |                                    |
| the skin and wires tethering    |                                    |
| the patient to a recorder. AJ   |                                    |
| Medical is seeking capital to   |                                    |
| complete FDA requirements,      |                                    |
| begin manufacture and marketing |                                    |
| of CardioAlarm, and develop the |                                    |
| next in a series of minimally   |                                    |
| invasive and wireless           |                                    |
| physiologic monitors.           |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Akaza Research**              | Cal Collins                        |
|                                 |                                    |
| Cambridge, MA                   | Tel: 617-621-8585                  |
|                                 |                                    |
| Industry Sector: Clinical       | Email: ccollins@akazaresearch.com  |
| Research                        |                                    |
+---------------------------------+------------------------------------+
| Akaza Research has developed    |                                    |
| OpenClinica, the leading open   |                                    |
| source clinical trial data      |                                    |
| capture and management software |                                    |
| platform. Akaza brings Open     |                                    |
| Source Software (OSS) into the  |                                    |
| mainstream of the clinical      |                                    |
| research enterprise by making   |                                    |
| robust, flexible,               |                                    |
| standards-based systems         |                                    |
| accessible for private and      |                                    |
| public research. Akaza Research |                                    |
| provides OpenClinica support,   |                                    |
| training, and consulting        |                                    |
| services to its customers       |                                    |
| worldwide.                      |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Allied Innovative Systems,    | Simon Bystryak                     |
| LLC**                           |                                    |
|                                 | Tel: 973-919-5707                  |
| Parsippany, NJ                  |                                    |
|                                 | Email: sbystryak@verizon.net       |
| Industry Sector: Diagnostics    |                                    |
+---------------------------------+------------------------------------+
| Allied Innovative Systems       |                                    |
| (ALLIS) is a research and       |                                    |
| development company engaged in  |                                    |
| the development of new          |                                    |
| technologies in the field of    |                                    |
| biochemical and biomedical      |                                    |
| assays and reagents. In         |                                    |
| particular, we have developed   |                                    |
| several techniques that         |                                    |
| increase the sensitivity of     |                                    |
| enzyme-mediated fundamental     |                                    |
| analytical assays. This work    |                                    |
| was supported by NIH SBIR       |                                    |
| grants. Now, we are in the      |                                    |
| process of negotiations         |                                    |
| regarding the commercialization |                                    |
| of these technologies with a    |                                    |
| market leader in biomedical     |                                    |
| diagnostics. Several novel      |                                    |
| biochemical assays, such as     |                                    |
| development of new homogeneous  |                                    |
| analytical assays based on      |                                    |
| generation of singlet oxygen    |                                    |
| and detection of fluorescence   |                                    |
| polarization, were also         |                                    |
| developed by ALLIS.             |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Applied Scientific Research** | Adrin Gharakhani                   |
|                                 |                                    |
| Santa Ana, CA                   | Tel: 949-752-7545                  |
|                                 |                                    |
| Industry Sector: Other          | Email:                             |
|                                 | adrin@Applied-Scientific.com       |
+---------------------------------+------------------------------------+
| Applied Scientific Research     |                                    |
| (ASR) develops state-of-the-art |                                    |
| user-friendly design and        |                                    |
| analysis software to simulate   |                                    |
| and visualize thermo-fluid      |                                    |
| dynamical processes of interest |                                    |
| to government and industrial    |                                    |
| clients in the environmental,   |                                    |
| bioengineering and medical      |                                    |
| products sectors, as well as    |                                    |
| the aerospace, automotive,      |                                    |
| maritime, and chemical fields.  |                                    |
| Additionally, ASR provides      |                                    |
| engineering consulting support  |                                    |
| to clients in the same fields.  |                                    |
| At present, ASR has NIH support |                                    |
| to develop a highly advanced    |                                    |
| \"virtual test chamber\" to     |                                    |
| investigate blood flow about    |                                    |
| mechanical heart valves under   |                                    |
| physiologically realistic flow  |                                    |
| conditions. Another NIH project |                                    |
| supports the development of     |                                    |
| software for simulating         |                                    |
| particulate-laden flow, such as |                                    |
| flow of platelets and red blood |                                    |
| cells in plasma as well as drug |                                    |
| particulates or aerosols in     |                                    |
| carrier fluid streams.          |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Archimage, Inc.**             | Richard Buday                      |
|                                 |                                    |
| Houston, TX                     | Tel: 713-523-3425                  |
|                                 |                                    |
| Industry Sector: Healthcare     | Email: RBuday@ArchimageOnline.com  |
| Media                           |                                    |
+---------------------------------+------------------------------------+
| Archimage is a                  |                                    |
| twenty-four-year-old design     |                                    |
| studio and winner of over       |                                    |
| thirty international awards for |                                    |
| architecture, television        |                                    |
| commercials, videogames,        |                                    |
| websites, and graphic           |                                    |
| design. The company is wrapping |                                    |
| up development of two           |                                    |
| videogames targeted to          |                                    |
| preventing obesity and type II  |                                    |
| diabetes in children.           |                                    |
|                                 |                                    |
| The rising incidence of type II |                                    |
| diabetes has reached epidemic   |                                    |
| proportions, especially among   |                                    |
| children and young adults.      |                                    |
| Causes are linked to poor diet  |                                    |
| and lack of exercise. Diabetes, |                                    |
| the leading cause of new        |                                    |
| blindness and kidney failure,   |                                    |
| is also the nation's sixth      |                                    |
| leading cause of death. The     |                                    |
| predicted societal and economic |                                    |
| impacts are staggering.         |                                    |
|                                 |                                    |
| Videogames are one of the       |                                    |
| fastest-growing businesses in   |                                    |
| the entertainment world.        |                                    |
| Research shows a majority of    |                                    |
| children and teenagers spend an |                                    |
| hour a day playing videogames.  |                                    |
| The average age videogame       |                                    |
| player is 33 years old.         |                                    |
|                                 |                                    |
| Archimage believes significant  |                                    |
| consumer markets exist for      |                                    |
| videogames that promote healthy |                                    |
| lifestyles.                     |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Atmospheric Glow              | Kimberly Kelly-Wintenberg          |
| Technologies, Inc.**            |                                    |
|                                 | Tel: 865-777-3776                  |
| Knoxville, TN                   |                                    |
|                                 | Email:                             |
| Industry Sector: Medical        | kwintenb@atmosphericglow.com       |
| Devices                         |                                    |
+---------------------------------+------------------------------------+
| Atmospheric Glow Technologies,  |                                    |
| Inc. (AGT) is a science and     |                                    |
| engineering company developing  |                                    |
| products based upon patented    |                                    |
| One Atmosphere Uniform Glow     |                                    |
| Discharge Plasma (OAUGDP^®^)    |                                    |
| technology. The company has     |                                    |
| assembled an experienced and    |                                    |
| diverse team of experienced     |                                    |
| officers and highly trained     |                                    |
| scientists and engineers        |                                    |
| committed to technology         |                                    |
| commercialization. AGT owns two |                                    |
| patents and has exclusive       |                                    |
| rights to eight patents. AGT's  |                                    |
| technology uses radio-frequency |                                    |
| electric power to generate      |                                    |
| plasma from air which in turn   |                                    |
| produces highly oxidative       |                                    |
| chemical species that can be    |                                    |
| used beneficially in several    |                                    |
| application areas. AGT's plasma |                                    |
| doesn't require special gases   |                                    |
| or vacuum conditions so it      |                                    |
| costs less to operate than      |                                    |
| other plasma technologies. AGT  |                                    |
| has introduced two products and |                                    |
| is working to commercialize     |                                    |
| other plasma products in the    |                                    |
| areas of biotechnology, medical |                                    |
| device sterilization, air       |                                    |
| purification, and disinfection  |                                    |
| of food and other agricultural  |                                    |
| products.                       |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **BioFormatix, Inc.**           | Dariusz Wroblewski                 |
|                                 |                                    |
| Escondido, CA                   | Tel: 858-248-2884                  |
|                                 |                                    |
| Industry Sector: Diagnostics    | Email: dariusz@bioformatix.com     |
+---------------------------------+------------------------------------+
| BioFormatix was founded and     |                                    |
| incorporated in 2004 as a       |                                    |
| research, product development   |                                    |
| and service company addressing  |                                    |
| the needs of biomedical         |                                    |
| markets. Our technology         |                                    |
| addresses challenging problems  |                                    |
| in data collection, data        |                                    |
| modeling, and software          |                                    |
| development.                    |                                    |
|                                 |                                    |
| The present product development |                                    |
| programs, funded by the NIH     |                                    |
| National Eye Institute,         |                                    |
| include:                        |                                    |
|                                 |                                    |
| \* Head mounted apparatus for   |                                    |
| the visual field testing.       |                                    |
|                                 |                                    |
| \* Diagnostic aid software for  |                                    |
| early detection of glaucoma     |                                    |
| from the visual field test.     |                                    |
|                                 |                                    |
| Other current interests         |                                    |
| include:                        |                                    |
|                                 |                                    |
| \* Computerized personal tools  |                                    |
| for weight management and       |                                    |
| diabetes management.            |                                    |
|                                 |                                    |
| \* Novel graphical computer     |                                    |
| interfaces.                     |                                    |
|                                 |                                    |
| \* Medical diagnostic aid       |                                    |
| software.                       |                                    |
|                                 |                                    |
| \* Bioinformatics and novel     |                                    |
| modeling approaches to analysis |                                    |
| of molecular expression data    |                                    |
| (metabonomic,                   |                                    |
| genomic/transcriptomic,         |                                    |
| proteomic).                     |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **BioHesion Inc.**              | Theo deVos                         |
|                                 |                                    |
| Seattle, WA                     | Tel: 206-235-3435                  |
|                                 |                                    |
| Industry Sector: Biotechnology  | Email: t.devos@biohesion.com       |
+---------------------------------+------------------------------------+
| BioHesion has developed         |                                    |
| expertise in surface chemistry  |                                    |
| with an emphasis on             |                                    |
| derivatizing inert surfaces     |                                    |
| with biomolecules. We have      |                                    |
| produced a number of            |                                    |
| recombinant proteins and        |                                    |
| peptides which bind gold        |                                    |
| through high affinity peptide   |                                    |
| tags, while retaining their     |                                    |
| biological activity. Based on   |                                    |
| this, we have developed         |                                    |
| Goldbinder technology for       |                                    |
| application in BioSensor and    |                                    |
| Biomaterials markets. We have   |                                    |
| developed sensor applications   |                                    |
| for surface plasmon resonance   |                                    |
| and colloidal gold to support   |                                    |
| commercialization of the        |                                    |
| technology. We are also         |                                    |
| establishing proof of principle |                                    |
| in animal models for Goldbinder |                                    |
| technology to enable            |                                    |
| Biomaterials with robust        |                                    |
| surface coatings for imaging    |                                    |
| and drug delivery.              |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Bioptigen, Inc.**             | Eric Buckland                      |
|                                 |                                    |
| Durham, NC                      | Tel: 919-314-5500                  |
|                                 |                                    |
| Industry Sector: Diagnostics    | Email: ebuckland@bioptigen.com     |
+---------------------------------+------------------------------------+
| Bioptigen\'s pioneering in vivo |                                    |
| optical imaging technology      |                                    |
| allows academic and life        |                                    |
| science researchers to see      |                                    |
| pathologies at their earliest   |                                    |
| stage with unprecedented detail |                                    |
| and clarity, across a wide      |                                    |
| range of subject applications.  |                                    |
| This sophisticated OCT hardware |                                    |
| and software system enables     |                                    |
| real-time non-invasive imaging  |                                    |
| of internal tissue              |                                    |
| microstructure at an unmatched  |                                    |
| level of precision and depth,   |                                    |
| and extends the application     |                                    |
| space to cover a wide range of  |                                    |
| human and animal subjects.      |                                    |
| These advances make it possible |                                    |
| for researchers to open up new  |                                    |
| avenues of biological           |                                    |
| exploration and development,    |                                    |
| and to foster advances in       |                                    |
| disease detection and           |                                    |
| management.                     |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Brown & Herbranson Imaging**  | Bob Austrian                       |
|                                 |                                    |
| Portola Valley, CA              | Tel: 415-794-1199                  |
|                                 |                                    |
| Industry Sector: Clinical       | Email: baustrian@hotmail.com       |
| Research                        |                                    |
+---------------------------------+------------------------------------+
| eHuman, Inc., and parent        |                                    |
| company Brown & Herbranson      |                                    |
| Imaging, are leading providers  |                                    |
| of 3-D interactive anatomical   |                                    |
| software applications, services |                                    |
| and human datasets for dental,  |                                    |
| medical and consumer markets.   |                                    |
| Our core products, already in   |                                    |
| use within 50% of U.S.-based    |                                    |
| dental schools, bring the       |                                    |
| latest volumetric computing,    |                                    |
| interactive visualization and   |                                    |
| learning solutions to the       |                                    |
| spatially complex field of      |                                    |
| dentistry. Based upon the       |                                    |
| educational and economic value  |                                    |
| of our initial products, we are |                                    |
| developing the industry's first |                                    |
| Web-based, haptics-enabled      |                                    |
| surgical simulator and digital  |                                    |
| curriculum platform, enabling a |                                    |
| first-in-class, 21st-century    |                                    |
| dental pedagogy. Additionally,  |                                    |
| working with partners including |                                    |
| the Stanford School of          |                                    |
| Medicine, Smithsonian and       |                                    |
| Max-Planck Institute, our       |                                    |
| eHuman.com subsidiary is        |                                    |
| developing the most             |                                    |
| comprehensive, research-class   |                                    |
| anatomical imaging, reference   |                                    |
| and digital learning library    |                                    |
| for broader health care         |                                    |
| applications.                   |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Caracal, Inc.**               | DerShung Yang                      |
|                                 |                                    |
| Buffalo Grove, IL               | Tel: 847-419-9288                  |
|                                 |                                    |
| Industry Sector: Healthcare     | Email: dyang@caracalinc.com        |
| Services                        |                                    |
+---------------------------------+------------------------------------+
| Caracal, Inc. is a premier      |                                    |
| research and development firm   |                                    |
| specialized in                  |                                    |
| healthcare-related innovative   |                                    |
| technology solutions to improve |                                    |
| patient outcomes, promote       |                                    |
| patient self-management,        |                                    |
| improve access to quality care, |                                    |
| and reduce healthcare costs.    |                                    |
| Our solutions are based on      |                                    |
| multidisciplinary approaches    |                                    |
| integrating patient-reported    |                                    |
| outcomes (PRO) research,        |                                    |
| e-health and telehealth         |                                    |
| technologies, evidence-based    |                                    |
| medicine, and patient education |                                    |
| and provider training practice. |                                    |
| Our solutions are developed     |                                    |
| with the collaboration from     |                                    |
| researchers and practitioners   |                                    |
| at more than a dozen top-rated  |                                    |
| research and patient care       |                                    |
| institutions. We are a main     |                                    |
| contributor to the endeavors    |                                    |
| integrating PRO solutions       |                                    |
| developed at the PROMIS         |                                    |
| Network, an NIH Roadmap         |                                    |
| project, into mainstream        |                                    |
| clinical practice.              |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Caring Technologies, Inc.**   | Ron Oberleitner                    |
|                                 |                                    |
| Boise, ID                       | Tel: 609-306-9181                  |
|                                 |                                    |
| Industry Sector: Telemedicine   | Email: rono@talkautism.org         |
+---------------------------------+------------------------------------+
| Caring Technologies, Inc.       |                                    |
| delivers a specialty web-based  |                                    |
| Personal Health Record (PHR)    |                                    |
| platform which is enhanced by   |                                    |
| its exclusive worldwide license |                                    |
| to a proprietary data capture   |                                    |
| system called BI Capture™. By   |                                    |
| delivering these via its        |                                    |
| popular online autism           |                                    |
| communication network           |                                    |
| TalkAutismTM, the Company will  |                                    |
| revolutionize behavioral        |                                    |
| medicine treatment and research |                                    |
| while providing enriched        |                                    |
| interaction between individuals |                                    |
| with autism and professionals   |                                    |
| who can be anywhere in the      |                                    |
| world. Stemming from its        |                                    |
| traction in the autism          |                                    |
| category, CT will apply this    |                                    |
| platform to other pressing      |                                    |
| health conditions, where the    |                                    |
| company can leverage this       |                                    |
| unique hybrid of technology     |                                    |
| services to facilitate          |                                    |
| treatment for Alzheimer's,      |                                    |
| Parkinson's, Traumatic Brain    |                                    |
| Injury, Post Traumatic Stress   |                                    |
| Disorder, and other costly      |                                    |
| neurological , neuromuscular    |                                    |
| and broader chronic illness     |                                    |
| populations. Ultimately, CT's   |                                    |
| technology platform will appeal |                                    |
| to the more general health      |                                    |
| marketplace directly or via     |                                    |
| sublicense.                     |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **CellASIC Corporation**        | Paul Hung                          |
|                                 |                                    |
| San Leandro, CA                 | Tel: 510-895-1985                  |
|                                 |                                    |
| Industry Sector:                | Email: pauljhung@cellasic.com      |
| Instrumentation                 |                                    |
+---------------------------------+------------------------------------+
| CellASIC's long term vision is  |                                    |
| to develop microfluidic         |                                    |
| products to foster the next     |                                    |
| wave of the life science        |                                    |
| revolution. In the 20th         |                                    |
| century, it became possible to  |                                    |
| isolate and study living        |                                    |
| components (DNA, proteins,      |                                    |
| cells) in a laboratory setting, |                                    |
| giving rise to the modern       |                                    |
| pharmaceutical industry. The    |                                    |
| next revolution in human        |                                    |
| biology will occur when         |                                    |
| controlled studies can be       |                                    |
| replicated in the laboratory    |                                    |
| that are capable of simulating  |                                    |
| behaviors of entire living      |                                    |
| system. The basic concept of    |                                    |
| CellASIC's technology is to     |                                    |
| create microfabricated cell     |                                    |
| culture environments to improve |                                    |
| the quality of laboratory       |                                    |
| experiments.                    |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **CFD Research Corporation**    | Shankar Sundaram                   |
|                                 |                                    |
| Huntsville, AL                  | Tel: 256-726-4892                  |
|                                 |                                    |
| Industry Sector:                | Email: sxs@cfdrc.com               |
| Pharmaceuticals                 |                                    |
+---------------------------------+------------------------------------+
| CFD Research Corporation        |                                    |
| (CFDRC) is the technology       |                                    |
| leader in advanced engineering  |                                    |
| solutions (software & hardware, |                                    |
| designs and prototypes) for     |                                    |
| diverse global businesses.      |                                    |
| CFDRC researches, develops and  |                                    |
| provides innovative solutions   |                                    |
| for:                            |                                    |
|                                 |                                    |
| \* Aerospace and Defense        |                                    |
|                                 |                                    |
| \* Biomedical and Life Sciences |                                    |
|                                 |                                    |
| \* Emerging Technologies        |                                    |
|                                 |                                    |
| Our products and services are   |                                    |
| used by over 500 organizations  |                                    |
| worldwide. To accelerate global |                                    |
| commercialization of matured    |                                    |
| simulation technologies, in     |                                    |
| 2004, CFDRC spun off its        |                                    |
| software products division.     |                                    |
| Presently, CFDRC has a highly   |                                    |
| qualified staff of over 90      |                                    |
| employees in Huntsville, AL,    |                                    |
| and active collaborations with  |                                    |
| over 30 research organizations  |                                    |
| worldwide.                      |                                    |
|                                 |                                    |
| In recognition of our           |                                    |
| commercialization successes, we |                                    |
| have been awarded the           |                                    |
| prestigious Tibbetts Award      |                                    |
| twice (latest one in 2006) and  |                                    |
| have been cited in the success  |                                    |
| stories of NASA, U.S. Navy, Air |                                    |
| Force, DARPA, NIH, NSF, and     |                                    |
| international magazines.        |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Creatv MicroTech, Inc.**      | Cha-Mei Tang                       |
|                                 |                                    |
| Potomac, MD                     | Tel: 301-983-1650                  |
|                                 |                                    |
| Industry Sector: Diagnostics    | Email: cmtang@creatvmicrotech.com  |
+---------------------------------+------------------------------------+
| Creatv MicroTech, Inc. is       |                                    |
| developing sensitive            |                                    |
| biodetection platforms.         |                                    |
| Creatv's vision is to become a  |                                    |
| major supplier of diagnostic    |                                    |
| tests, analytical tools and     |                                    |
| reagents for the water, food,   |                                    |
| environmental, pharmaceutical   |                                    |
| and medical industries. Creatv  |                                    |
| achieves innovations through    |                                    |
| both independent and joint      |                                    |
| research & development with     |                                    |
| universities and research       |                                    |
| laboratories. Creatv also       |                                    |
| performs development in         |                                    |
| microfabrication. Creatv        |                                    |
| manufactures advanced x-ray     |                                    |
| anti-scatter grids and nuclear  |                                    |
| collimators to improve medical  |                                    |
| imaging and received R&D 100    |                                    |
| Award in 2006 for these         |                                    |
| products.                       |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Danya International, Inc.**   | David Sherry                       |
|                                 |                                    |
| Silver Spring, MD               | Tel: 301-565-2142                  |
|                                 |                                    |
| Industry Sector: Healthcare     | Email: dsherry@danya.com           |
| Services                        |                                    |
+---------------------------------+------------------------------------+
| Danya International, Inc.,      |                                    |
| designs and implements          |                                    |
| breakthrough solutions through  |                                    |
| the creative use of multimedia  |                                    |
| communications, information     |                                    |
| technology, and evidence based  |                                    |
| research. Our mission is to     |                                    |
| have a social impact on public  |                                    |
| health and education. As a      |                                    |
| social impact company, Danya    |                                    |
| dedicates its resources and     |                                    |
| talent toward the impact on six |                                    |
| social goals: reduce tobacco,   |                                    |
| alcohol, and other drug use and |                                    |
| addiction; improve the quality  |                                    |
| of comprehensive early          |                                    |
| childhood education; enhance    |                                    |
| child and family health;        |                                    |
| promote mental health           |                                    |
| education; reduce rates of new  |                                    |
| HIV infections and other        |                                    |
| infectious diseases; and        |                                    |
| promote diversity and inclusion |                                    |
| in everything we do.\           |                                    |
| The Multi-Problem Youth (MPY)   |                                    |
| screening and assessment system |                                    |
| is an innovative user friendly  |                                    |
| tool designed to be rapidly     |                                    |
| administered to adolescents by  |                                    |
| primary care and mental health  |                                    |
| providers. This product offers  |                                    |
| an engaging use of technology   |                                    |
| which is unique in the          |                                    |
| screening and assessment        |                                    |
| marketplace.                    |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **DEKK-TEC, Inc.**              | Lee Roy Morgan                     |
|                                 |                                    |
| New Orleans, LA                 | Tel: 504-583-6135                  |
|                                 |                                    |
| Industry Sector:                | Email: LRM1579@aol.com             |
| Pharmaceuticals                 |                                    |
+---------------------------------+------------------------------------+
| DEKK-TEC is a R&D company that  |                                    |
| has been designing and          |                                    |
| developing new anticancer drugs |                                    |
| and delivery systems since      |                                    |
| the early 1980s. We have the    |                                    |
| ability to design, synthesize,  |                                    |
| test and prepare agents for     |                                    |
| pre-clinical studies and then   |                                    |
| finalize their IND              |                                    |
| applications. Two of our drugs  |                                    |
| are in Phase II trials (in      |                                    |
| collaboration with Tigris       |                                    |
| Pharmaceuticals and Ziopharm    |                                    |
| Oncology) and a third is ready  |                                    |
| to enter Phase 1 trials. To     |                                    |
| date we taken three drugs       |                                    |
| through IND and into clinical   |                                    |
| trials. We also have two        |                                    |
| devices for which we prepared   |                                    |
| the 510K applications and       |                                    |
| assisted with their licensing.  |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Dimera, Inc.**                | R. Kent Hermsmeyer                 |
|                                 |                                    |
| Portland, OR                    | Tel: 503-295-2775                  |
|                                 |                                    |
| Industry Sector: Biotechnology  | Email: rkh@dimera.net              |
+---------------------------------+------------------------------------+
| Dimera Incorporated is a        |                                    |
| grant-funded biotech company    |                                    |
| developing formulations to      |                                    |
| address angina pectoris and     |                                    |
| myocardial ischemia in women.   |                                    |
| Dimera was founded by Dr R Kent |                                    |
| Hermsmeyer and investment       |                                    |
| partners in Portland, Oregon in |                                    |
| 1997, based on observations     |                                    |
| that primate coronary           |                                    |
| reactivity was suppressed to    |                                    |
| normal physiological range by   |                                    |
| low-dose replacement of         |                                    |
| progesterone, but not           |                                    |
| medroxyprogesterone acetate.    |                                    |
| These independently verified    |                                    |
| studies demonstrate that        |                                    |
| considerable improvement of     |                                    |
| coronary function can result    |                                    |
| from progesterone replacement   |                                    |
| even with low doses, thus       |                                    |
| offering a well-tolerated,      |                                    |
| logical, effective option to    |                                    |
| current therapies.              |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **EduMedia, Inc.**              | Martin McCarthy, Jr.               |
|                                 |                                    |
| Evanston, IL                    | Tel: 847-475-1988                  |
|                                 |                                    |
| Industry Sector: Healthcare     | Email: mmcc@northwestern.edu       |
| Media                           |                                    |
+---------------------------------+------------------------------------+
| EduMedia is an e-health company |                                    |
| specializing in the prevention  |                                    |
| of disease and the promotion of |                                    |
| wellness. We create tailored    |                                    |
| educational programs for        |                                    |
| high-risk populations that      |                                    |
| maintain the health status of   |                                    |
| users and produce cost-savings  |                                    |
| for employers. Our current      |                                    |
| areas of focus are skin cancer, |                                    |
| breast cancer, diabetes, low    |                                    |
| back pain, and depression.      |                                    |
| Evidence-based behavioral       |                                    |
| interventions, effective        |                                    |
| educational strategies, and     |                                    |
| engaging multimedia content are |                                    |
| used to deliver high impact     |                                    |
| solutions with low unit costs.  |                                    |
| We seek strategic partnerships  |                                    |
| with providers of corporate     |                                    |
| wellness services,              |                                    |
| forward-looking managed care    |                                    |
| organizations, high-volume      |                                    |
| insurers and payers, and        |                                    |
| established e-health companies. |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Energetiq Technology, Inc.**  | Paul Blackborow                    |
|                                 |                                    |
| Woburn, MA                      | Tel: 781-939-0763                  |
|                                 |                                    |
| Industry Sector: Diagnostics    | Email: pblackborow@energetiq.com   |
+---------------------------------+------------------------------------+
| Energetiq is a developer and    |                                    |
| manufacturer of advanced short  |                                    |
| wavelength light sources that   |                                    |
| enable nano-scale structures    |                                    |
| and products. Used in complex   |                                    |
| scientific and engineering      |                                    |
| applications, Energetiq\'s      |                                    |
| light products are based on new |                                    |
| technology that generates high  |                                    |
| brightness and high power light |                                    |
| in the 1nm to 400nm range with  |                                    |
| high reliability in a compact   |                                    |
| package. Energetiq has          |                                    |
| primarily been developing       |                                    |
| technology and products for the |                                    |
| semiconductor industry.         |                                    |
| Energetiq is interested in      |                                    |
| introducing this technology and |                                    |
| expertise into the life         |                                    |
| sciences and medical community. |                                    |
+---------------------------------+------------------------------------+

+-----------------------------------+----------------------------------+
| **Engineering and Scientific      | Jafar Vossoughi                  |
| Research Associates**             |                                  |
|                                   | Tel: 301-570-9771                |
| Olney, MD                         |                                  |
|                                   | Email: vossoughi@verizon.net     |
| Industry Sector: Biotechnology    |                                  |
+-----------------------------------+----------------------------------+
| The main activity of the company  |                                  |
| is R&D related to medical         |                                  |
| products.                         |                                  |
+-----------------------------------+----------------------------------+

+---------------------------------+------------------------------------+
| **Genego**                      | Yuri Nikolsky                      |
|                                 |                                    |
| Saint Joseph, MI                | Tel: 858-829-6239                  |
|                                 |                                    |
| Industry Sector: Diagnostics    | Email: yuri@genego.com             |
+---------------------------------+------------------------------------+
| GeneGo is a leading provider of |                                    |
| data mining & analysis          |                                    |
| solutions in systems biology.   |                                    |
| Our tools and databases help to |                                    |
| capture and define the          |                                    |
| underlying biology behind       |                                    |
| different types of              |                                    |
| high-throughput experimental    |                                    |
| data and understand the effects |                                    |
| of small molecule drug          |                                    |
| compounds in human tissues. We  |                                    |
| provide systems biology         |                                    |
| solutions for a full range of   |                                    |
| applications in life science    |                                    |
| research and drug development,  |                                    |
| from pre-clinical discovery and |                                    |
| NCE applications to clinical    |                                    |
| trials, covering all aspects of |                                    |
| biology and chemistry.          |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Genopsys**                    | Eric Lietz                         |
|                                 |                                    |
| Soquel, CA                      | Tel: 831-462-4390                  |
|                                 |                                    |
| Industry Sector: Biotechnology  | Email: ejlietz@genopsys.com        |
+---------------------------------+------------------------------------+
| Genopsys is a privately held    |                                    |
| company developing proprietary  |                                    |
| diversity technologies to       |                                    |
| rapidly optimize novel protein  |                                    |
| products. Genopsys is focused   |                                    |
| on commercializing molecules    |                                    |
| that promise to transform the   |                                    |
| way disease is detected,        |                                    |
| treated, and managed in cancer  |                                    |
| and disorders of the central    |                                    |
| nervous system.                 |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **HealthCare Interactive,       | John Hobday                        |
| Inc.**                          |                                    |
|                                 | Tel: 612-709-7777                  |
| Edina, MN                       |                                    |
|                                 | Email: jhobday@hcinteractive.com   |
| Industry Sector: Healthcare     |                                    |
| Media                           |                                    |
+---------------------------------+------------------------------------+
| HealthCare Interactive is       |                                    |
| committed to developing the     |                                    |
| most innovative set of          |                                    |
| dementia-related training       |                                    |
| programs available on the       |                                    |
| market today. To accomplish     |                                    |
| this, HCI has developed         |                                    |
| comprehensive Web-based, DVD,   |                                    |
| and CD-ROM delivered            |                                    |
| educational programs for        |                                    |
| patients, caregivers, and       |                                    |
| professional health workers     |                                    |
| (doctors, nurses, aides, and    |                                    |
| individuals involved in the     |                                    |
| care of the elderly or          |                                    |
| demented). HCI\'s software      |                                    |
| programs are unique,            |                                    |
| innovative, research-based, and |                                    |
| research-validated. Each        |                                    |
| program has won wide acclaim    |                                    |
| from family members and         |                                    |
| professional caregivers alike.  |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Immunomedics, Inc.**          | Cynthia Sullivan                   |
|                                 |                                    |
| Morris Plains, NJ               | Tel: 973 605-8200                  |
|                                 |                                    |
| Industry Sector: Biotechnology  | Email: csullivan@immunomedics.com  |
+---------------------------------+------------------------------------+
| Immunomedics is a New           |                                    |
| Jersey-based, publicly-traded   |                                    |
| (NASDAQ:IMMU) biopharmaceutical |                                    |
| company focused on the          |                                    |
| development of monoclonal       |                                    |
| antibody-based products for the |                                    |
| targeted treatment of cancer,   |                                    |
| autoimmune and other serious    |                                    |
| diseases. We have developed a   |                                    |
| number of proprietary           |                                    |
| technologies that allow us to   |                                    |
| create humanized antibodies     |                                    |
| that can be used either alone   |                                    |
| in unlabeled or "naked" form,   |                                    |
| or conjugated with radioactive  |                                    |
| isotopes, chemotherapeutics or  |                                    |
| toxins, in each case to create  |                                    |
| highly targeted agents. Using   |                                    |
| these technologies, we have     |                                    |
| built a pipeline of therapeutic |                                    |
| product candidates that utilize |                                    |
| several different mechanisms of |                                    |
| action.                         |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Infinite Biomedical           | Santosh Venkatesha                 |
| Technologies, LLC**             |                                    |
|                                 | Tel: 410-889-8011                  |
| Baltimore, MD                   |                                    |
|                                 | Email: santosh@i-biomed.com        |
| Industry Sector: Medical        |                                    |
| Devices                         |                                    |
+---------------------------------+------------------------------------+
| Infinite Biomedical             |                                    |
| Technologies was founded in     |                                    |
| 1997 and is headquartered in    |                                    |
| Baltimore, Maryland. IBT is     |                                    |
| deeply motivated to solve       |                                    |
| important clinical problems by  |                                    |
| translating research            |                                    |
| discoveries into commercially   |                                    |
| available medical products      |                                    |
| through device sales and        |                                    |
| intellectual property           |                                    |
| licensing. With this 'bench to  |                                    |
| bedside' philosophy, the        |                                    |
| company focuses on three        |                                    |
| distinct business lines: global |                                    |
| asphyxia, neurocritical care &  |                                    |
| intraoperative monitoring, and  |                                    |
| long-term monitoring. IBT's     |                                    |
| mission is to become the        |                                    |
| leading supplier of innovative  |                                    |
| instrumentation, software, and  |                                    |
| services for quantitative       |                                    |
| neurodiagnostics.               |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Infoscitex Corporation**      | David Montella                     |
|                                 |                                    |
| Waltham, MA                     | Tel: 781-890-1338                  |
|                                 |                                    |
| Industry Sector: Medical        | Email: dmontella@infoscitex.com    |
| Devices                         |                                    |
+---------------------------------+------------------------------------+
| IST is a research, development, |                                    |
| and engineering firm providing  |                                    |
| technology solutions and        |                                    |
| services for defense, life      |                                    |
| science, and energy &           |                                    |
| environment customers. IST's    |                                    |
| scientists and engineers have   |                                    |
| an established record of        |                                    |
| developing technologies from    |                                    |
| concept to reality and          |                                    |
| delivering high-value           |                                    |
| solutions. Core focus areas and |                                    |
| services include: Drug          |                                    |
| Enhancement & Delivery,         |                                    |
| Electromechanical Systems,      |                                    |
| Information Technology,         |                                    |
| Communications, Electronics,    |                                    |
| Material Processing, Medical    |                                    |
| Devices, Robotics, Sensors,     |                                    |
| Research, Development,          |                                    |
| Commercialization/Transition,   |                                    |
| Engineering, Systems            |                                    |
| Analysis/Design, Quality        |                                    |
| Assurance, Independent          |                                    |
| Test/Validation, Technology     |                                    |
| Support, Modeling/Simulation,   |                                    |
| Technology Assessment, Software |                                    |
| Development, and Systems        |                                    |
| Integration. Infoscitex has 60  |                                    |
| employees, and is headquartered |                                    |
| in Waltham, MA                  |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **INFOTECH Soft, Inc.**         | Patrick Shironoshita               |
|                                 |                                    |
| Miami, FL                       | Tel: 305-670-5111                  |
|                                 |                                    |
| Industry Sector: Healthcare     | Email:                             |
|                                 | Pat                                |
|                                 | rick.Shironoshita@infotechsoft.com |
+---------------------------------+------------------------------------+
| INFOTECH Soft, Inc. creates     |                                    |
| innovative software solutions   |                                    |
| for healthcare and the life     |                                    |
| sciences. We continuously       |                                    |
| expand the state of the art in  |                                    |
| information technology and      |                                    |
| computer engineering to create  |                                    |
| tools that enhance the          |                                    |
| productivity of health          |                                    |
| professionals and institutions. |                                    |
| Our products focus on the       |                                    |
| collection, processing and      |                                    |
| management of clinical trial    |                                    |
| data, and on the integration of |                                    |
| information from diverse and    |                                    |
| disparate sources into a        |                                    |
| comprehensive, unified semantic |                                    |
| environment.                    |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Innovative Biologics, Inc.**  | Jeff Conroy                        |
|                                 |                                    |
| Herndon, VA                     | Tel: 703-346-0751                  |
|                                 |                                    |
| Industry Sector: Biotechnology  | Email: jxc@adjuvant.com            |
+---------------------------------+------------------------------------+
| Innovative Biologics, Inc. is   |                                    |
| an anti-infective small         |                                    |
| molecule drug company targeting |                                    |
| microbes producing pore-forming |                                    |
| toxins, such as MRSA and        |                                    |
| Hepatitis C. IBI\'s CycloPlex™  |                                    |
| platform identifies compounds   |                                    |
| which inhibit their action,     |                                    |
| based on blocking the target    |                                    |
| pore with molecules having the  |                                    |
| same symmetry as the pore       |                                    |
| itself, using ß-cyclodextrin as |                                    |
| a scaffold.                     |                                    |
|                                 |                                    |
| IBI has been funded with \$1.8  |                                    |
| million in NIH grants. IBI\'s   |                                    |
| initial focus was drug          |                                    |
| discovery targeting anthrax and |                                    |
| other microbes producing        |                                    |
| pore-forming toxins. IBI has    |                                    |
| ongoing programs in anthrax and |                                    |
| clostridium perfringens.        |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Intrinsic Bioprobes Inc.**    | Monte Cain                         |
|                                 |                                    |
| Tempe, AZ                       | Tel: 425-337-2580                  |
|                                 |                                    |
| Industry Sector: Biotechnology  | Email: monte@intrinsicbio.com      |
+---------------------------------+------------------------------------+
| Intrinsic Bioprobes Inc. is an  |                                    |
| Arizona based biotech company   |                                    |
| that has developed proprietary  |                                    |
| tools and techniques enabling   |                                    |
| high-throughput protein         |                                    |
| analysis and characterization   |                                    |
| for biomarker and proteomic     |                                    |
| discovery. Mass Spectrometric   |                                    |
| Immunoassay (MSIA™ - Tips) are  |                                    |
| affinity pipettes that          |                                    |
| selectively isolate proteins    |                                    |
| out of complex biological       |                                    |
| fluids. Bioreactive Probes      |                                    |
| (BRP™) are specialized 96 well  |                                    |
| plates that modify proteins in  |                                    |
| a way that is ideal for mass    |                                    |
| spec analysis. Incorporated     |                                    |
| into the MASSAY® System and     |                                    |
| using robotic processes, our    |                                    |
| system is capable of analyzing  |                                    |
| up to 2,500 samples per day of  |                                    |
| proteins obtained directly from |                                    |
| biological media. IBI's         |                                    |
| integrated resources turn       |                                    |
| protein analysis into a major   |                                    |
| strategic advantage by          |                                    |
| revealing the protein and       |                                    |
| protein variants associated     |                                    |
| with disease. These             |                                    |
| technologies apply directly to  |                                    |
| drug development, research      |                                    |
| programs, diagnostics and       |                                    |
| clinical trial evaluations.     |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Investigen**                  | Heather Koshinsky                  |
|                                 |                                    |
| Hercules, CA                    | Tel: 510-964-9700                  |
|                                 |                                    |
| Industry Sector: Diagnostics    | Email: ceo@investigen.com          |
+---------------------------------+------------------------------------+
| Investigen is an R&D company    |                                    |
| dedicated to improve upon       |                                    |
| existing technologies and       |                                    |
| develop new Molecular           |                                    |
| Diagnostic tools. Investigen is |                                    |
| developing a proprietary        |                                    |
| smartDNA™; Molecular Diagnostic |                                    |
| platform. While smartDNA can be |                                    |
| used in laboratories, its       |                                    |
| simplicity should make it       |                                    |
| uniquely able to serve in       |                                    |
| diagnostic tests that can be    |                                    |
| used away from a central lab    |                                    |
| (in peripheral labs, at the POC |                                    |
| or at the point of sample       |                                    |
| collection (POS)).              |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **InvoTek, Inc.**               | Thomas Jakobs                      |
|                                 |                                    |
| Alma, AR                        | Tel: 479-632-4166                  |
|                                 |                                    |
| Industry Sector: Other          | Email: tjakobs@invotek.org         |
+---------------------------------+------------------------------------+
| InvoTek specializes in          |                                    |
| technology-based solutions that |                                    |
| meet the needs of people with   |                                    |
| disabilities. InvoTek and our   |                                    |
| partners have concentrated on   |                                    |
| developing new ways for people  |                                    |
| to access computers when        |                                    |
| standard access methods (mouse  |                                    |
| and keyboard) are impossible.   |                                    |
| We have demonstrated the        |                                    |
| feasibility of four new         |                                    |
| technologies, including: 1) A   |                                    |
| 3-D tracking system that        |                                    |
| enables a person to control the |                                    |
| position of a computer cursor   |                                    |
| using head movement. 2) A very  |                                    |
| low cost eye-tracking system    |                                    |
| that enables people to control  |                                    |
| the position of a computer      |                                    |
| cursor using eye movement. 3) A |                                    |
| dysarthric speech recognition   |                                    |
| system that, when used in       |                                    |
| conjunction with word           |                                    |
| prediction techniques, reduces  |                                    |
| the number of letters a user    |                                    |
| must enter by 70% when typing   |                                    |
| text into a computer. 4) A      |                                    |
| large-area, light-sensing       |                                    |
| surface that enabled InvoTek to |                                    |
| design eye-safe laser systems   |                                    |
| for entering text into          |                                    |
| computers and controlling       |                                    |
| speech generating devices.      |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **ISW Group, Inc.**             | Monique Spann-Wade                 |
|                                 |                                    |
| St. Louis, MO                   | Tel: 314-812-8033                  |
|                                 |                                    |
| Industry Sector:                | Email: monique@iswgroup.com        |
| Pharmaceuticals                 |                                    |
+---------------------------------+------------------------------------+
| ISW Group was founded in 2001   |                                    |
| and is a privately held St.     |                                    |
| Louis-based company. ISW's      |                                    |
| mission is to research,         |                                    |
| develop, and market             |                                    |
| FDA-approved topical products   |                                    |
| designed to manage and treat    |                                    |
| acute and chronic inflammatory  |                                    |
| skin conditions. ISW has        |                                    |
| developed a patented technology |                                    |
| platform that targets a         |                                    |
| therapeutically effective dose  |                                    |
| of drug to relevant dermal      |                                    |
| targets while minimizing        |                                    |
| systemic effects. ISW has       |                                    |
| completed FDA pre-clinical and  |                                    |
| clinical safety studies for its |                                    |
| lead product for the management |                                    |
| and treatment of                |                                    |
| Pseudofolliculitis barbae       |                                    |
| (PFB), a potentially            |                                    |
| debilitating dermatologic       |                                    |
| condition. Additionally, ISW's  |                                    |
| technology platform is expected |                                    |
| to be useful for a variety of   |                                    |
| skin conditions including acne  |                                    |
| keloidalis, boils, dermatitis   |                                    |
| (eczema), rosacea, and burns.   |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Jambeyang Research**          | Weiwen Lin                         |
|                                 |                                    |
| Cupertino, CA                   | Tel: 408-446-0598                  |
|                                 |                                    |
| Industry Sector: Healthcare     | Email: wlin@jambeyang.com          |
+---------------------------------+------------------------------------+
| Jambeyang Research is a         |                                    |
| healthcare information          |                                    |
| technology company that was     |                                    |
| founded to develop innovative   |                                    |
| data collection and reporting   |                                    |
| solutions for the healthcare    |                                    |
| providers and researchers. Our  |                                    |
| first product, Breast Imaging   |                                    |
| Data System, provides           |                                    |
| streamlined data collection     |                                    |
| (from patients, office clerks,  |                                    |
| technologists and               |                                    |
| radiologists), report           |                                    |
| generation and distribution,    |                                    |
| and MQSA support functions that |                                    |
| are expected to improve the     |                                    |
| quality of electronic medical   |                                    |
| records, patient communication, |                                    |
| as well as the overall          |                                    |
| efficiency of breast imaging    |                                    |
| exams. This product includes    |                                    |
| several patentable technologies |                                    |
| that can be adopted for other   |                                    |
| applications.                   |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Leo Lens Technology**         | Praful Doshi                       |
|                                 |                                    |
| San Diego, CA                   | Tel: 858-335-2873                  |
|                                 |                                    |
| Industry Sector: Medical        | Email: pdoshi@leolens.com          |
| Devices                         |                                    |
+---------------------------------+------------------------------------+
| Leo Lens Technology, founded in |                                    |
| 2001, has innovated the next    |                                    |
| generation of specialty         |                                    |
| coatings for contact lenses to  |                                    |
| create additional market of     |                                    |
| more than billion dollars.      |                                    |
| Using enabling inkjet printing  |                                    |
| technology, we have developed   |                                    |
| contact lenses that provide an  |                                    |
| exact digital image of an iris  |                                    |
| with true colors on the lens    |                                    |
| for cosmetic application &/or   |                                    |
| antimicrobial coating for       |                                    |
| healthier eye &/or comfort      |                                    |
| enhancement for increased use.  |                                    |
| We provide multiple benefits to |                                    |
| the consumer, optometrist and   |                                    |
| manufacturer. Our growing       |                                    |
| patent portfolio of more than   |                                    |
| 20 patents is comprehensive and |                                    |
| global. We have [FDA            |                                    |
| approval.]{.underline} We       |                                    |
| provide multiple benefits to    |                                    |
| the consumer, optometrist and   |                                    |
| manufacturer. Leo Lens          |                                    |
| Technology is looking for a     |                                    |
| strategic and financial partner |                                    |
| for commercialization.          |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **LightSpin Technologies,       | Eric Harmon                        |
| Inc.**                          |                                    |
|                                 | Tel: 508-809-9052                  |
| Norfolk, MA                     |                                    |
|                                 | Email: harmon@lightspintech.com    |
| Industry Sector: Diagnostics    |                                    |
+---------------------------------+------------------------------------+
| LightSpin Technologies, Inc.    |                                    |
| develops the world's highest    |                                    |
| performance solid-state photon  |                                    |
| detectors, achieving single     |                                    |
| photon sensitivity, high        |                                    |
| quantum efficiency, wide        |                                    |
| dynamic range, large            |                                    |
| photosensitive area and low     |                                    |
| noise. LightSpin's photon       |                                    |
| detectors will supplant         |                                    |
| fragile, expensive, high        |                                    |
| voltage photomultiplier tubes   |                                    |
| with a low cost, low voltage,   |                                    |
| robust, solid-state solution.   |                                    |
| These photon detectors are      |                                    |
| critical components for a wide  |                                    |
| range of light starved          |                                    |
| applications, including         |                                    |
| biomedical instruments,         |                                    |
| chemical analysis instruments,  |                                    |
| and PET scanners.               |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Menssana Research, Inc.**     | Michael Phillips                   |
|                                 |                                    |
| Fort Lee, NJ                    | Tel: 201-886-7004                  |
|                                 |                                    |
| Industry Sector: Diagnostics    | Email:                             |
|                                 | mphillips@menssanaresearch.com     |
+---------------------------------+------------------------------------+
| Menssana Research develops      |                                    |
| advanced new breath tests for   |                                    |
| the detection of disease. This  |                                    |
| includes:                       |                                    |
|                                 |                                    |
| a\. Hardware for the collection |                                    |
| of volatile organic compounds   |                                    |
| (VOCs) in breath                |                                    |
|                                 |                                    |
| b\. Hardware for the analysis   |                                    |
| of VOCs in breath               |                                    |
|                                 |                                    |
| c\. Software: algorithms for    |                                    |
| interpretation of the results   |                                    |
| of analysis of VOCs in breath   |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Micron Optics, Inc.**         | Kevin Hsu                          |
|                                 |                                    |
| Atlanta, GA                     | Tel: 404-325-0005                  |
|                                 |                                    |
| Industry Sector: Diagnostics    | Email: khsu@micronoptics.com       |
+---------------------------------+------------------------------------+
| Micron Optics Inc. (MOI), a     |                                    |
| leading provider of tunable     |                                    |
| optical technologies, offers a  |                                    |
| comprehensive portfolio of      |                                    |
| components and instruments for  |                                    |
| sensing, telecom, and biotech   |                                    |
| markets. MOI is a vertically    |                                    |
| integrated company that         |                                    |
| conducts applied research,      |                                    |
| development, manufacturing,     |                                    |
| marketing, and sales.           |                                    |
|                                 |                                    |
| With over 17 years of           |                                    |
| dedication, Micron Optics has   |                                    |
| generated tunable technologies  |                                    |
| to provide best-in-class        |                                    |
| optical resolution, accuracy,   |                                    |
| transmission profile, and       |                                    |
| dynamic range. The resulting    |                                    |
| platforms enable a suite of     |                                    |
| innovative products including   |                                    |
| tunable filter and fiber        |                                    |
| grating sensor components,      |                                    |
| swept laser and optical sensing |                                    |
| modules and instruments for use |                                    |
| in optical networks and         |                                    |
| fiber-optic sensing systems.    |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **MicroSurfaces, Inc.**         | Athena Guo                         |
|                                 |                                    |
| Minneapolis, MN                 | Tel: 612-789-0104                  |
|                                 |                                    |
| Industry Sector: Diagnostics    | Email: athena@memsurface.com       |
+---------------------------------+------------------------------------+
| MicroSurfaces, Inc. develops    |                                    |
| and markets surface             |                                    |
| technologies for biochips and   |                                    |
| MEMS. In biochips, we supply    |                                    |
| functionalized surfaces for     |                                    |
| biomolecule immobilization on   |                                    |
| glass slides, coverslips,       |                                    |
| silicon wafers, ITO, 96 well    |                                    |
| plate, etc., to research        |                                    |
| institutes and pharmaceutical   |                                    |
| companies. We also provide      |                                    |
| customized coating services for |                                    |
| a wide variety of surface       |                                    |
| functionalities, materials, and |                                    |
| devices. The applications for   |                                    |
| our customers includes, among   |                                    |
| others,                         |                                    |
| protein/peptide/antibody        |                                    |
| arrays, biosensor, single       |                                    |
| molecule spectroscopy,          |                                    |
| microfluidics, and ELISA. Our   |                                    |
| coatings feature the lowest     |                                    |
| background possible (academic & |                                    |
| commercial combined).           |                                    |
| MicroSurfaces is seeking        |                                    |
| capital investment and          |                                    |
| partnership to extend product   |                                    |
| applications in drug discovery  |                                    |
| and disease diagnostic markets. |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Mimosa Acoustics, Inc.**      | Patricia Jeng                      |
|                                 |                                    |
| Champaign, IL                   | Tel: 217-367-9740                  |
|                                 |                                    |
| Industry Sector: Medical        | Email: klrust@mimosaacoustics.com  |
| Devices                         |                                    |
+---------------------------------+------------------------------------+
| Mimosa's main mission and       |                                    |
| interest is in research,        |                                    |
| development and manufacturing   |                                    |
| of preventive inner and middle  |                                    |
| ear diagnostics. Mimosa prefers |                                    |
| to work with strategic partners |                                    |
| in the hearing health care      |                                    |
| industry to market our          |                                    |
| technology. The technology      |                                    |
| developed by Mimosa for         |                                    |
| measuring wide-band acoustic    |                                    |
| ear-canal input impedance has   |                                    |
| important implications and      |                                    |
| applications in the             |                                    |
| audiological diagnostic and     |                                    |
| rehabilitative markets. Mimosa  |                                    |
| plans to develop each of those  |                                    |
| areas and will provide novel    |                                    |
| methods to improve the health   |                                    |
| care in the hearing related     |                                    |
| areas.                          |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Molecular Design              | William Purcell                    |
| International, Inc.**           |                                    |
|                                 | Tel: 901-529-1919                  |
| Memphis, TN                     |                                    |
|                                 | Email: purcell@moleculardesign.com |
| Industry Sector:                |                                    |
| Pharmaceuticals                 |                                    |
+---------------------------------+------------------------------------+
| Molecular Design                |                                    |
| International's (MDI) business  |                                    |
| model is to discover small      |                                    |
| molecule therapies and to       |                                    |
| out-license them to larger      |                                    |
| biopharmaceutical companies for |                                    |
| continued development and       |                                    |
| commercialization. This         |                                    |
| approach allows MDI to maintain |                                    |
| a highly cost-effective         |                                    |
| approach to creating innovative |                                    |
| treatments for various          |                                    |
| conditions, while benefiting    |                                    |
| from the ultimate               |                                    |
| commercialization of those      |                                    |
| discoveries through milestone   |                                    |
| and royalty bearing agreements. |                                    |
|                                 |                                    |
| Since 1991 MDI has completed    |                                    |
| six licensing agreements with   |                                    |
| various biopharmaceutical       |                                    |
| development companies including |                                    |
| Glaxo, Eli Lilly, and J&J. Much |                                    |
| of MDI's success has been made  |                                    |
| possible through ten SBIR/STTR  |                                    |
| grants ranging from Phase 1 to  |                                    |
| Phase 3.                        |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Nanotherapeutics, Inc.**      | James Talton                       |
|                                 |                                    |
| Alachua, FL                     | Tel: 386-462-9663                  |
|                                 |                                    |
| Industry Sector:                | Email:                             |
| Pharmaceuticals                 | jtalton@nanotherapeutics.com       |
+---------------------------------+------------------------------------+
| Nanotherapeutics Inc. is an     |                                    |
| emerging specialty              |                                    |
| pharmaceutical company with     |                                    |
| expertise in the early stage    |                                    |
| development of pharmaceuticals. |                                    |
| The company employs several     |                                    |
| platform technologies to        |                                    |
| manipulate and enhance the      |                                    |
| properties of drugs. These      |                                    |
| technologies can be employed    |                                    |
| with new chemical entities or   |                                    |
| with generic drugs and can be   |                                    |
| used with the spectrum of       |                                    |
| existing drug types ranging     |                                    |
| from small synthetic molecules  |                                    |
| to large recombinant            |                                    |
| macromolecules.                 |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Novaflux Technologies**       | Charles Brumlik                    |
|                                 |                                    |
| Princeton, NJ                   | Tel: 609-683-0215                  |
|                                 |                                    |
| Industry Sector: Healthcare     | Email: brumlik@novaflux.com        |
| Media                           |                                    |
+---------------------------------+------------------------------------+
| Princeton Trade and Technology, |                                    |
| Inc. d/b/a Novaflux             |                                    |
| Technologies is a Princeton,    |                                    |
| NJ-based, medical device and    |                                    |
| technology company founded in   |                                    |
| 1988 by Dr. Mohamed E. Labib.   |                                    |
| To date, the Company has        |                                    |
| received over \$6.0 million     |                                    |
| from SBIR grants from various   |                                    |
| government agencies including   |                                    |
| the National Institutes of      |                                    |
| Health (NIH), contract research |                                    |
| and development (R&D) projects, |                                    |
| and licensing. These monies     |                                    |
| were used to develop the        |                                    |
| "two-phase flow" technology     |                                    |
| platform and hemodialyzer and   |                                    |
| endoescope reprocessors. The    |                                    |
| Company has 8 US patents on     |                                    |
| two-phase flow technology,      |                                    |
| methods, compositions, and      |                                    |
| devices.                        |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Omicia, Inc.**                | Nomi Harris                        |
|                                 |                                    |
| Emeryville, CA                  | Tel: 510-595-0800                  |
|                                 |                                    |
| Industry Sector: Diagnostics    | Email: nharris@omicia.com          |
+---------------------------------+------------------------------------+
| Omicia, Inc. is a life sciences |                                    |
| company developing technologies |                                    |
| and products that translate an  |                                    |
| individual\'s unique genetic    |                                    |
| makeup into clinically          |                                    |
| actionable information. The     |                                    |
| company\'s proprietary system   |                                    |
| identifies sets of genetic      |                                    |
| variations that are associated  |                                    |
| with increased disease risk or  |                                    |
| differences in drug response.   |                                    |
| After clinically validating     |                                    |
| these associations, Omicia      |                                    |
| combines the complex genetic    |                                    |
| signatures into a single risk   |                                    |
| index for each disease or       |                                    |
| treatment, helping to guide     |                                    |
| important medical decisions and |                                    |
| achieve superior outcomes for   |                                    |
| each individual. Omicia is a    |                                    |
| privately held company located  |                                    |
| in Emeryville, California.      |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Omneuron, Inc.**              | Christopher deCharms               |
|                                 |                                    |
| Menlo Park, CA                  | Tel: 650-585-5303                  |
|                                 |                                    |
| Industry Sector: Medical        | Email: cdecharms@omneuron.com      |
| Devices                         |                                    |
+---------------------------------+------------------------------------+
| Omneuron is a life sciences     |                                    |
| technology company pioneering   |                                    |
| the use of functional brain     |                                    |
| imaging for therapeutic         |                                    |
| intervention. Omneuron is       |                                    |
| developing methods to translate |                                    |
| the exciting progress made in   |                                    |
| functional MRI brain imaging    |                                    |
| during the past decade into     |                                    |
| clinical applications. The      |                                    |
| Omneuron research team works at |                                    |
| a state of the art research     |                                    |
| facility, with the benefit of   |                                    |
| access to our own 3T MRI        |                                    |
| scanner, the support of six NIH |                                    |
| grants, exciting technology,    |                                    |
| and fantastic collaborators. We |                                    |
| are currently carrying out      |                                    |
| clinical trials using real-time |                                    |
| functional MRI in two           |                                    |
| therapeutic areas.              |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Oxford Biomedical Research,   | Denis Callewaert                   |
| Inc.**                          |                                    |
|                                 | Tel: 248-852-8815                  |
| Rochester Hills, MI             |                                    |
|                                 | Email: dcallew@oxfordbiomed.com    |
| Industry Sector: Biotechnology  |                                    |
+---------------------------------+------------------------------------+
| Oxford Biomedical Research      |                                    |
| (OBR), founded in 1984,         |                                    |
| develops and manufactures high  |                                    |
| quality biological reagents and |                                    |
| assay kits for the life science |                                    |
| research market. OBR markets    |                                    |
| over 1,000 products worldwide.  |                                    |
| OBR's primary focus is in the   |                                    |
| development of assays for       |                                    |
| biomarkers for oxidative stress |                                    |
| and chronic inflammation.       |                                    |
| Several products have been      |                                    |
| developed with SBIR/STTR        |                                    |
| funding involving               |                                    |
| collaborations with             |                                    |
| internationally recognized      |                                    |
| scientists. Ongoing research    |                                    |
| also includes development of    |                                    |
| improved proteomics methods for |                                    |
| the rapid depletion of high     |                                    |
| abundance serum proteins and    |                                    |
| for the isolation and           |                                    |
| quantification of               |                                    |
| oxidatively-modified proteins,  |                                    |
| for which multiple patent       |                                    |
| applications are pending.       |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Perinatronics Medical         | Thomas Frank                       |
| Systems, Inc.**                 |                                    |
|                                 | Tel: 410-987-1305                  |
| Millersville, MD                |                                    |
|                                 | Email: tfrank@perinatronics.com    |
| Industry Sector: Medical        |                                    |
| Devices                         |                                    |
+---------------------------------+------------------------------------+
| Perinatronics Medical Systems,  |                                    |
| Inc., is a small high-tech      |                                    |
| company involved in the         |                                    |
| hardware and software           |                                    |
| development of electronic       |                                    |
| medical instrumentation,        |                                    |
| including the fields of         |                                    |
| electrocardiography, fetal      |                                    |
| heart rate monitoring and       |                                    |
| magnetic resonance imaging.     |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Photon Migration              | Randall Barbour                    |
| Technologies**                  |                                    |
|                                 | Tel: 718-270-1286                  |
| Glen Head, NY                   |                                    |
|                                 | Email: rbarbour@downstate.edu      |
| Industry Sector: Medical        |                                    |
| Devices                         |                                    |
+---------------------------------+------------------------------------+
| We are pioneering the           |                                    |
| development of a new            |                                    |
| economical, portable, and       |                                    |
| scalable assessment modality    |                                    |
| that can provide novel insights |                                    |
| about integrated body function, |                                    |
| early detection of disease      |                                    |
| states and actions of           |                                    |
| pharmaceutical agents. Central  |                                    |
| to this capability is the       |                                    |
| ability to explore, in          |                                    |
| real-time, the complex          |                                    |
| interactions between tissue and |                                    |
| its blood supply. To capture    |                                    |
| this information we have        |                                    |
| designed a proprietary          |                                    |
| measurement and analysis        |                                    |
| platform that can be applied to |                                    |
| tissue sizes that range from    |                                    |
| small animals to man (infants   |                                    |
| to adults) and equine           |                                    |
| populations. Our technology is  |                                    |
| economical, compact, portable   |                                    |
| and noninvasive.                |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **PICS, Inc.**                  | Al Behar                           |
|                                 |                                    |
| Reston, VA                      | Tel: 703-758-1795                  |
|                                 |                                    |
| Industry Sector:                | Email: albehar@lifesign.com        |
| Pharmaceuticals                 |                                    |
+---------------------------------+------------------------------------+
| PICS, Inc. is a health          |                                    |
| technology company best known   |                                    |
| for its LifeSign**®** family of |                                    |
| consumer products addressing    |                                    |
| tobacco cessation               |                                    |
| (QuitKey**®**), healthy diet    |                                    |
| and exercise (DietMate**®**)    |                                    |
| and insomnia (SleepKey**®**).   |                                    |
| LifeSign® has enjoyed worldwide |                                    |
| market acceptance as evidenced  |                                    |
| by over 1.25 million units sold |                                    |
| generating over 100 million     |                                    |
| dollars in sales. PICS          |                                    |
| is poised now to greatly save   |                                    |
| time and money for the research |                                    |
| and clinical communities with   |                                    |
| the introduction of             |                                    |
| CERTAS**®**, a researcher -     |                                    |
| configurable fully integrated   |                                    |
| EDC system utilizing eDiaries,  |                                    |
| wireless technology and         |                                    |
| Interactive Voice Recognition.  |                                    |
| The uniqueness of               |                                    |
| CERTAS® will accelerate the     |                                    |
| design and management of        |                                    |
| clinical studies. PICS is       |                                    |
| seeking a partner with the      |                                    |
| marketing muscle to exploit the |                                    |
| large potential for CERTAS**®** |                                    |
| in the CRO and pharmaceutical   |                                    |
| industries.                     |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Point Vista Software**        | RJ Harrison                        |
|                                 |                                    |
| Oakland, CA                     | Tel: 510-508-9746                  |
|                                 |                                    |
| Industry Sector: Diagnostics    | Email: rjharrison@pointvista.biz   |
+---------------------------------+------------------------------------+
| The members of PVS have a long  |                                    |
| history of success working with |                                    |
| each other in various companies |                                    |
| and on consulting engagements   |                                    |
| -- the longest dating back 16   |                                    |
| years when 2 of the founders    |                                    |
| met while at Sybase Europe.     |                                    |
| With vast expertise in the      |                                    |
| healthcare space, development   |                                    |
| of electronic medical records   |                                    |
| systems, databases, smart       |                                    |
| cards, business applications,   |                                    |
| and process engineering the PVS |                                    |
| is focused on continuing to     |                                    |
| find ways to improve patient    |                                    |
| care through the proper use of  |                                    |
| technology.                     |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Potomac Affinity Proteins,    | Bonnie Bryan                       |
| LLC**                           |                                    |
|                                 | Tel: 301-601-9687                  |
| North Potomac, MD               |                                    |
|                                 | Email: potomac_affinity@msn.com    |
| Industry Sector: Biotechnology  |                                    |
+---------------------------------+------------------------------------+
| Potomac Affinity Proteins, a    |                                    |
| research and development        |                                    |
| company, has developed          |                                    |
| proprietary methods to engineer |                                    |
| high-specificity, processing    |                                    |
| proteases. Potomac has already  |                                    |
| developed a protease/affinity   |                                    |
| tag technology for purifying    |                                    |
| proteins of scientific and      |                                    |
| pharmaceutical interest. This   |                                    |
| technology will benefit         |                                    |
| structural genomics efforts     |                                    |
| which rely on high-throughput,  |                                    |
| parallel processing of samples, |                                    |
| large-scale purification of     |                                    |
| pharmaceutical proteins, and    |                                    |
| rapid production of vaccines in |                                    |
| response to naturally-emergent  |                                    |
| (e.g., avian flu) and           |                                    |
| intentionally-introduced        |                                    |
| pathogens (e.g.,                |                                    |
| bio-terrorism). Future          |                                    |
| development will focus on       |                                    |
| proteases for use in biosensors |                                    |
| and therapeutics.               |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Powerscope, Inc.**            | Amir Naqwi                         |
|                                 |                                    |
| Minneapolis, MN                 | Tel: 612-331-4247                  |
|                                 |                                    |
| Industry Sector: Medical        | Email: anaqwi@powerscopetech.com   |
| Devices                         |                                    |
+---------------------------------+------------------------------------+
| Powerscope was founded in 2001  |                                    |
| and has the following mission   |                                    |
| statement: To research,         |                                    |
| develop, demonstrate and        |                                    |
| license out products and        |                                    |
| processes of value to the       |                                    |
| industry, in particular,        |                                    |
| medical device industry and     |                                    |
| pharmaceutical industry.        |                                    |
|                                 |                                    |
| Currently, Powerscope offers a  |                                    |
| product, FibrSizr, for         |                                    |
| in-process real-time            |                                    |
| measurement of the diameters of |                                    |
| polymer and glass fibers. Also  |                                    |
| a drug nanoparticle generator   |                                    |
| for pre-clinical studies is     |                                    |
| developed and would be offered  |                                    |
| in 2008 through a vendor of     |                                    |
| pre-clinical research           |                                    |
| equipment.                      |                                    |
|                                 |                                    |
| Powerscope has technical        |                                    |
| strengths in optical            |                                    |
| diagnostics, aerosol mechanics  |                                    |
| and fluid mechanics. Although   |                                    |
| the company envisions           |                                    |
| commercialization of newly      |                                    |
| developed technologies through  |                                    |
| licensing, Powerscope personnel |                                    |
| have background in small-scale  |                                    |
| manufacturing, as well as sales |                                    |
| and marketing. These skills are |                                    |
| helpful in introducing new      |                                    |
| products in the marketplace,    |                                    |
| before long-term licensing      |                                    |
| arrangements are made.          |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Precision Bioassay**          | David Lansky                       |
|                                 |                                    |
| Burlington, VT                  | Tel: 802-865-0155                  |
|                                 |                                    |
| Industry Sector: Other          | Email: david@precisionbioassay.com |
+---------------------------------+------------------------------------+
| We provide statistical          |                                    |
| solutions to practical problems |                                    |
| in biological assay. We provide |                                    |
| consulting services for design, |                                    |
| development, analysis, and      |                                    |
| validation of biological        |                                    |
| assays. By combining good       |                                    |
| design of bioassays and         |                                    |
| validation experiments with our |                                    |
| analysis methods (partially     |                                    |
| based on our proprietary        |                                    |
| software) we reduce the time    |                                    |
| needed for development and      |                                    |
| validation of biological assays |                                    |
| while simultaneously improving  |                                    |
| their precision. This           |                                    |
| combination reduces the risk of |                                    |
| development for biological      |                                    |
| products, and by improving the  |                                    |
| precision of biological assays, |                                    |
| reduces the routine cost of     |                                    |
| these assays.                   |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Prognosys Biosciences**       | Charlie Lieu                       |
|                                 |                                    |
| La Jolla, CA                    | Tel: 858-459-2428                  |
|                                 |                                    |
| Industry Sector: Biotechnology  | Email: clieu@prognosysbio.com      |
+---------------------------------+------------------------------------+
| Prognosys Biosciences is        |                                    |
| developing innovative assay     |                                    |
| technologies in the             |                                    |
| pharmacogenomics and chemical   |                                    |
| genomic space for life sciences |                                    |
| research and development.       |                                    |
|                                 |                                    |
| Our strategy is to:             |                                    |
|                                 |                                    |
| 1\) Develop and make available  |                                    |
| novel assays for applications   |                                    |
| ranging from basic research to  |                                    |
| clinical diagnostics            |                                    |
|                                 |                                    |
| 2\) Use them to discover and    |                                    |
| validate molecular markers that |                                    |
| have prognostic value           |                                    |
|                                 |                                    |
| 3\) Commercialize products and  |                                    |
| services that are               |                                    |
| transformative for life         |                                    |
| sciences applications           |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Protein Discovery, Inc.**     | Chuck Witkowski                    |
|                                 |                                    |
| Knoxville, TN                   | Tel: 865-521-7400                  |
|                                 |                                    |
| Industry Sector: Clinical       | Email: chuck@proteindiscovery.com  |
| Research                        |                                    |
+---------------------------------+------------------------------------+
| Protein Discovery, Inc. (PDI)   |                                    |
| is a privately-held life        |                                    |
| sciences company providing      |                                    |
| proprietary sample preparation  |                                    |
| solutions for clinical mass     |                                    |
| spectrometry. The company is    |                                    |
| headquartered in Knoxville, TN  |                                    |
| and employees 12 individuals.   |                                    |
| PDI has developed three unique  |                                    |
| sample preparation platforms:   |                                    |
| (1) imaging mass spectrometry   |                                    |
| (IMS), (2) specialty reagents   |                                    |
| for protein research using mass |                                    |
| spectrometry, and (3) its       |                                    |
| MALDIplex(TM) M5 Sample Prep    |                                    |
| Station. IMS is currently       |                                    |
| offered as a service and the    |                                    |
| reagents are sold as products.  |                                    |
| Both currently produce          |                                    |
| operational cash flow.          |                                    |
| MALDIplex is scheduled for      |                                    |
| product launch in Q1 2008.      |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Rapid Micro Biosystems**      | Stephen Delity/Don Straus          |
|                                 |                                    |
| Bedford, MA                     | Tel: 781-271-1444                  |
|                                 |                                    |
| Industry Sector: Diagnostics    | Email: sdelity@rapidmicrobio.com,  |
|                                 |                                    |
|                                 | dstraus@rapidmicrobio.com          |
+---------------------------------+------------------------------------+
| The company is developing       |                                    |
| innovative automated testing    |                                    |
| platforms that deliver rapid,   |                                    |
| ultra-sensitive detection of    |                                    |
| infection and disease markers   |                                    |
| to address needs in the         |                                    |
| clinical and biodefense         |                                    |
| markets. The company has        |                                    |
| launched its first product, the |                                    |
| Growth Direct^TM^ System, which |                                    |
| rapidly detects microbiological |                                    |
| contamination in pharmaceutical |                                    |
| products. With this product     |                                    |
| launch, the company is          |                                    |
| reorganizing its personnel and  |                                    |
| assets into two operating       |                                    |
| companies. Rapid Micro          |                                    |
| Biosystems will focus on the    |                                    |
| Industrial Microbiology market  |                                    |
| and First Light Biosciences     |                                    |
| will focus on developing its    |                                    |
| technology for applications in  |                                    |
| the clinical and biodefense     |                                    |
| markets.                        |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **SANARIA INC.**                | David Dolberg                      |
|                                 |                                    |
| Rockville, MD                   | Tel: (510) 685-6405                |
|                                 |                                    |
| Industry Sector: Biotechnology  | Email: ddolberg@Sanaria.com        |
+---------------------------------+------------------------------------+
| Sanaria Inc. is the only        |                                    |
| company in the World dedicated  |                                    |
| to the development and          |                                    |
| deployment of a vaccine against |                                    |
| *Plasmodium falciparum*         |                                    |
| malaria, and the vaccine under  |                                    |
| development is the only current |                                    |
| approach which has a            |                                    |
| demonstrated efficacy in humans |                                    |
| and the potential for \> 90%    |                                    |
| prevention of infection. The    |                                    |
| vaccine comprises live          |                                    |
| radiation-attenuated *P.        |                                    |
| falciparum* parasites.\         |                                    |
| Sanaria has produced its first  |                                    |
| lot of cGMP product. We have    |                                    |
| now moved into a 23000 square   |                                    |
| foot facility which includes a  |                                    |
| cGMP plant for manufacturing    |                                    |
| vaccine. We currently have a    |                                    |
| staff of approximately 37       |                                    |
| dedicated individuals including |                                    |
| 12 PhDs and/or MDs.             |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **SciTech Development, LLC**    | Earle Holsapple                    |
|                                 |                                    |
| Detroit, MI                     | Tel: 313-938-5517                  |
|                                 |                                    |
| Industry Sector:                | Email: eth@scitechdevelopment.com  |
| Pharmaceuticals                 |                                    |
+---------------------------------+------------------------------------+
| SciTech's mission is to         |                                    |
| optimize previously shelved     |                                    |
| anticancer drugs and develop    |                                    |
| them for specific indicated     |                                    |
| uses. This optimization and     |                                    |
| development process resulted in |                                    |
| the creation of SciTech\'s      |                                    |
| novel drug delivery and         |                                    |
| pancreatic cancer products.     |                                    |
| This work has been accomplished |                                    |
| by a diverse team of scientists |                                    |
| and business leaders formally   |                                    |
| associated with the Karmanos    |                                    |
| Cancer Institute.               |                                    |
|                                 |                                    |
| In addition to the drug         |                                    |
| development work, SciTech has   |                                    |
| conducted comparative drug      |                                    |
| toxicity testing studies on     |                                    |
| bone marrow from several        |                                    |
| species for various drug        |                                    |
| development organizations       |                                    |
| including the NCI.              |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **sComm**                       | Jason Curry                        |
|                                 |                                    |
| Independence, MO                | Tel: 816-350-7008                  |
|                                 |                                    |
| Industry Sector: Healthcare     | Email: jason@scommonline.com       |
+---------------------------------+------------------------------------+
| sComm, Inc develops, engineers, |                                    |
| and manufactures the UbiDuo     |                                    |
| Face to Face Communicator. The  |                                    |
| UbiDuo enables a deaf/hard of   |                                    |
| hearing and a hearing           |                                    |
| individual to communicate with  |                                    |
| each other face to face without |                                    |
| the need of an interpreter. The |                                    |
| goal is to allow deaf, hard of  |                                    |
| hearing, and others with        |                                    |
| communication barriers to       |                                    |
| strike up a conversation with   |                                    |
| hearing people anywhere anytime |                                    |
| such in professional or social  |                                    |
| communication situations. The   |                                    |
| UbiDuo changes the landscape    |                                    |
| for face to face communication. |                                    |
| The development of the UbiDuo   |                                    |
| was funded by a grant from the  |                                    |
| National Institute on Deafness  |                                    |
| and Other Communication         |                                    |
| Disorders with the National     |                                    |
| Institute of Health. sComm was  |                                    |
| founded by father and son out   |                                    |
| of frustration when they both   |                                    |
| were trying to converse with    |                                    |
| each other over breakfast on    |                                    |
| Saturday morning 5 years ago.   |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **SVision, LLC**                | James Lee                          |
|                                 |                                    |
| Bellevue, WA                    | Tel: 425-450-1014                  |
|                                 |                                    |
| Industry Sector:                | Email: jamesl@svisionllc.com       |
| Instrumentation                 |                                    |
+---------------------------------+------------------------------------+
| SVision LLC provides the        |                                    |
| next-generation image-based     |                                    |
| decision technology and         |                                    |
| products that solve the most    |                                    |
| difficult challenges in         |                                    |
| industrial inspection,          |                                    |
| measurement and alignment, cell |                                    |
| and tissue analysis, dynamic    |                                    |
| image bioinformatics, and data  |                                    |
| mining applications. SVision is |                                    |
| a technological innovator with  |                                    |
| 29 issued, 1 allowed and 16     |                                    |
| pending US patents. Since 1999, |                                    |
| SVision has been pioneering the |                                    |
| use of machine learning         |                                    |
| technology in a broad range of  |                                    |
| practical image recognition     |                                    |
| applications. SVision develops  |                                    |
| and markets the next generation |                                    |
| microscopy image analysis       |                                    |
| software, SVCell, whose         |                                    |
| development is partially funded |                                    |
| by the National Institute of    |                                    |
| Health (NIH) under multiple     |                                    |
| Small Business Innovative       |                                    |
| Research programs.              |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Tanglewood Research, Inc.**   | William Hansen                     |
|                                 |                                    |
| Greensboro, NC                  | Tel: 336-662-0090                  |
|                                 |                                    |
| Industry Sector: Healthcare     | Email: billhansen@tanglewood.net   |
+---------------------------------+------------------------------------+
| Tanglewood Research, Inc. has   |                                    |
| as its mission to translate     |                                    |
| behavioral technology into      |                                    |
| practical applications in the   |                                    |
| area of health promotion. The   |                                    |
| company focuses on the develop  |                                    |
| of products and services in     |                                    |
| three interdependent areas:     |                                    |
| effective programming to        |                                    |
| promote wellness and the        |                                    |
| prevention of risky behaviors,  |                                    |
| tools for conducting research   |                                    |
| and evaluation to assess the    |                                    |
| effectiveness of health and     |                                    |
| wellness interventions          |                                    |
| (particularly for adolescents), |                                    |
| and the professional            |                                    |
| development of health promotion |                                    |
| and prevention service          |                                    |
| providers.                      |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **TDA Research, Inc.**          | Steven Dietz                       |
|                                 |                                    |
| Wheat Ridge, CO                 | Tel: 303-940-2312                  |
|                                 |                                    |
| Industry Sector:                | Email: sdietz@tda.com              |
| Pharmaceuticals                 |                                    |
+---------------------------------+------------------------------------+
| TDA Research, Inc. develops     |                                    |
| advanced materials and chemical |                                    |
| processes that it can either    |                                    |
| manufacture or license. TDA has |                                    |
| been in operation for 20 years, |                                    |
| and employs 70 people, nearly   |                                    |
| all with degrees in either      |                                    |
| chemistry or engineering. In    |                                    |
| the past four years we have     |                                    |
| licensed and commercialized two |                                    |
| major processes, the multi-ton  |                                    |
| manufacture of fullerenes and a |                                    |
| partial oxidation process that  |                                    |
| removes sulfur from natural     |                                    |
| gas, both of which have         |                                    |
| multi-million dollar per year   |                                    |
| sales. Last year, annual sales  |                                    |
| by our partners of products     |                                    |
| developed at TDA with SBIR      |                                    |
| funding exceeded \$4.5 million. |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **TechniScan, Inc.**            | David Robinson                     |
|                                 |                                    |
| Salt Lake City, UT              | Tel: 801-521-0444                  |
|                                 |                                    |
| Industry Sector: Diagnostics    | Email:                             |
|                                 | drobinson@techniscanmedical.com    |
+---------------------------------+------------------------------------+
| TechniScan Medical Systems      |                                    |
| (TMS) is a privately held       |                                    |
| medical device company engaged  |                                    |
| in the development and          |                                    |
| commercialization of a          |                                    |
| revolutionary ultrasound        |                                    |
| imaging system, UltraSound CTTM |                                    |
| (WBUTM), to aid in the          |                                    |
| diagnosis of breast cancer.     |                                    |
| TMS' imaging system is designed |                                    |
| to provide physicians with a    |                                    |
| new, non-invasive, diagnostic   |                                    |
| imaging tool that will provide  |                                    |
| detailed information about the  |                                    |
| anatomy (i.e. physical          |                                    |
| structures within the breast)   |                                    |
| and pathology (i.e. bulk tissue |                                    |
| properties). The system is      |                                    |
| intended to be used as an       |                                    |
| adjunct to mammography to aid   |                                    |
| physicians in diagnosing breast |                                    |
| cancer by helping to            |                                    |
| differentiate normal or benign  |                                    |
| from malignant tissue in the    |                                    |
| breast.                         |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **The Virtual Reality Medical   | Mark Wiederhold                    |
| Center**                        |                                    |
|                                 | Tel: 858-642-0267                  |
| San Diego, CA                   |                                    |
|                                 | Email: mwiederhold@vrphobia.com    |
| Industry Sector: Medical        |                                    |
| Devices                         |                                    |
+---------------------------------+------------------------------------+
| The Virtual Reality Medical     |                                    |
| Center, with clinics in San     |                                    |
| Diego, Los Angeles, and Palo    |                                    |
| Alto is a world leader in       |                                    |
| applying virtual reality        |                                    |
| technology in combination with  |                                    |
| physiological monitoring and    |                                    |
| feedback. VRMC                  |                                    |
| software/hardware technology is |                                    |
| used for:                       |                                    |
|                                 |                                    |
| \*Evaluation and treatment of   |                                    |
| patients with anxiety disorders |                                    |
|                                 |                                    |
| \*Distraction for patients with |                                    |
| acute or chronic pain           |                                    |
|                                 |                                    |
| \*Treatment of returning        |                                    |
| veterans with posttraumatic     |                                    |
| stress disorder                 |                                    |
|                                 |                                    |
| \*Cognitive rehabilitation of   |                                    |
| patients with traumatic brain   |                                    |
| injury                          |                                    |
|                                 |                                    |
| Clinical studies, both          |                                    |
| published and in progress, show |                                    |
| that this technology is safe,   |                                    |
| effective, and cost effective,  |                                    |
| because VR can speed the        |                                    |
| attainment of desired outcomes. |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Transtimulation Research      | Jiande Chen                        |
| Inc.**                          |                                    |
|                                 | Tel: 832-640-8111                  |
| Oklahoma City, OK               |                                    |
|                                 | Email:                             |
| Industry Sector: Medical        | jiandechen@transtimulation.com     |
| Devices                         |                                    |
+---------------------------------+------------------------------------+
| Transtimulation Research Inc.   |                                    |
| is a startup company based in   |                                    |
| Oklahoma City. The mission of   |                                    |
| the company is to develop novel |                                    |
| methods for the diagnosis and   |                                    |
| treatment of digestive          |                                    |
| disorders and obesity.          |                                    |
| Currently, the company has been |                                    |
| working on electrical           |                                    |
| stimulator for the treatment of |                                    |
| obesity. Particularly the       |                                    |
| company has a number filed      |                                    |
| patents on new methodologies    |                                    |
| for the treatment of obesity    |                                    |
| using electrical stimulation of |                                    |
| the gut. In addition, the       |                                    |
| company is also working new     |                                    |
| methods of electrical           |                                    |
| stimulation for the treatment   |                                    |
| of diabetes and functional      |                                    |
| gastrointestinal disorders.     |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **TSRL, Inc.**                  | Elke Lipka                         |
|                                 |                                    |
| Ann Arbor, MI                   | Tel: 734-663-4233                  |
|                                 |                                    |
| Industry Sector: Biotechnology  | Email: elipka@tsrlinc.com          |
+---------------------------------+------------------------------------+
| Therapeutic Systems Research    |                                    |
| Laboratories (TSRL), Inc. is a  |                                    |
| pharmaceutical research firm,   |                                    |
| specializing in oral drug       |                                    |
| delivery, drug transport and    |                                    |
| biopharmaceutical properties of |                                    |
| drug delivery. We have          |                                    |
| developed a variety of          |                                    |
| formulations for improved oral  |                                    |
| drug delivery, including        |                                    |
| pulsatile drug release          |                                    |
| technology, the Programmable    |                                    |
| Oral Release Technology (PORT)  |                                    |
| Capsule, and water insoluble    |                                    |
| drug technology. TSRL, Inc.     |                                    |
| developed PK simulation         |                                    |
| software for the pharmaceutical |                                    |
| and biotechnology industries.   |                                    |
| More recently we have focused   |                                    |
| on prodrug strategies as well   |                                    |
| as the development of a carrier |                                    |
| technology, the Bile Acid       |                                    |
| Conjugate (BAC), which enable   |                                    |
| oral delivery of highly polar   |                                    |
| and/or charged drug candidates. |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Urovalve, Inc.**              | Harvey Homan                       |
|                                 |                                    |
| Newark, NJ                      | Tel: 973-596-1350                  |
|                                 |                                    |
| Industry Sector: Medical        | Email: harveydhoman@urovalve.com   |
| Devices                         |                                    |
+---------------------------------+------------------------------------+
| Urovalve is an early stage      |                                    |
| company whose mission is to     |                                    |
| design, develop, and            |                                    |
| commercialize superior medical  |                                    |
| devices that address problems   |                                    |
| with urinary flow and control.  |                                    |
| Urinary retention can be caused |                                    |
| by neuromuscular problems that  |                                    |
| impair the ability to relax the |                                    |
| urinary sphincters or by        |                                    |
| physical obstructions to the    |                                    |
| urethra, and affects up to 6    |                                    |
| million men. Urovalve\'s        |                                    |
| innovative intraurethral        |                                    |
| valved-catheter is designed to  |                                    |
| return control of bladder       |                                    |
| emptying to the user, therefore |                                    |
| improving quality of life and   |                                    |
| reducing urinary tract          |                                    |
| infection risk. The             |                                    |
| commercialization of this       |                                    |
| Surinate® device will launch    |                                    |
| Urovalve into the urology       |                                    |
| segment of the medical device   |                                    |
| industry.                       |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **VPDiagnostics, Inc.**         | Hui Hu                             |
|                                 |                                    |
| Seattle, WA                     | Tel: 206-428-6160                  |
|                                 |                                    |
| Industry Sector: Diagnostics    | Email: hui@vpdiagnostics.com       |
+---------------------------------+------------------------------------+
| VPDiagnostics, Inc. develops    |                                    |
| software products that          |                                    |
| identify, analyze and visualize |                                    |
| the dangerous vulnerable plaque |                                    |
| responsible for most strokes.   |                                    |
| Leveraging patented             |                                    |
| technologies and collaboration  |                                    |
| with our university research    |                                    |
| partners, we have a unique      |                                    |
| product that employs MRI for    |                                    |
| imaging and analyzing           |                                    |
| atherosclerosis in vivo; and    |                                    |
| that has been undergone         |                                    |
| extensive pathological          |                                    |
| validation. Our product is the  |                                    |
| only one specialized in plaque  |                                    |
| characterization within the     |                                    |
| arterial wall with the carotid  |                                    |
| arteries as the initial area of |                                    |
| application.                    |                                    |
|                                 |                                    |
| Our mission is to improve       |                                    |
| stroke prevention by providing  |                                    |
| a critical tool to better       |                                    |
| estimate the risks of most      |                                    |
| strokes. VPDiagnostics is       |                                    |
| achieving its goal through an   |                                    |
| experienced team, innovative    |                                    |
| technologies, application       |                                    |
| focused design, quality         |                                    |
| execution, and clinical and     |                                    |
| industrial partnership.         |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Ximerex, Inc.**               | William Beschorner                 |
|                                 |                                    |
| Blair, NE                       | Tel: 402-426-0660                  |
|                                 |                                    |
| Industry Sector: Biotechnology  | Email: beschorner@ximerex.com      |
+---------------------------------+------------------------------------+
| Ximerex, Inc. proposes to       |                                    |
| satisfy a major unmet need in   |                                    |
| organ and tissue                |                                    |
| transplantation. Using the      |                                    |
| tools of hematopoietic stem     |                                    |
| cells, cell therapy, and        |                                    |
| xenotransplantation, the        |                                    |
| Company has developed           |                                    |
| proprietary technology to       |                                    |
| transplant tissues from pigs    |                                    |
| without the need for drugs to   |                                    |
| prevent rejection.              |                                    |
|                                 |                                    |
| Hematopoietic stem cells from   |                                    |
| the patient are processed and   |                                    |
| grown within fetal pigs. The    |                                    |
| human T regulatory cells from   |                                    |
| the injected pig are later      |                                    |
| isolated and transferred back   |                                    |
| into the patient, conveying     |                                    |
| specific tolerance to the donor |                                    |
| pig. Subsequently, pig tissue   |                                    |
| is transplanted into the        |                                    |
| patient. The technology is      |                                    |
| useful for type 1 diabetes,     |                                    |
| heart failure, etc.             |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **XL Sci-Tech, Inc.**           | Y. Benjamin Peng                   |
|                                 |                                    |
| Richland, WA                    | Tel: 509-531-3558                  |
|                                 |                                    |
| Industry Sector: Medical        | Email: BenPeng@XLSciTech.com       |
| Devices                         |                                    |
+---------------------------------+------------------------------------+
| XL Sci-Tech develops and        |                                    |
| produces timed bioabsorbable    |                                    |
| radioactive devices for the     |                                    |
| treatment of soft tissue        |                                    |
| cancers. It has developed a     |                                    |
| protectable timed-bioabsorbable |                                    |
| biomaterial platform along with |                                    |
| a proprietary micro-fabrication |                                    |
| process for radioactive         |                                    |
| materials. The first            |                                    |
| application is the creation of  |                                    |
| BetaSpheres®, which consists of |                                    |
| timed-bioabsorbable Y-90        |                                    |
| microspheres for treatment of   |                                    |
| inoperable hepatocellular       |                                    |
| carcinoma (HCC) and metastatic  |                                    |
| liver cancer. The application   |                                    |
| of timed-bioabsorbable delivery |                                    |
| of Pd-103 for prostate cancer   |                                    |
| and other soft tissue cancers   |                                    |
| expands the scope of            |                                    |
| brachytherapy and makes         |                                    |
| timed-bioabsorbable matrix a    |                                    |
| true encapsulation and delivery |                                    |
| platform for gamma emitters, as |                                    |
| well as beta emitters.          |                                    |
| Timed-bioabsorbable             |                                    |
| brachytherapy seeds advance the |                                    |
| state-of-the-art and offer      |                                    |
| critical new treatment options  |                                    |
| that are no possible with the   |                                    |
| current seed technologies.      |                                    |
+---------------------------------+------------------------------------+

+---------------------------------+------------------------------------+
| **Zylon Medical Devices**       | Jack Klein                         |
|                                 |                                    |
| Chestnut Ridge, NY              | Tel: 845-425-9469                  |
|                                 |                                    |
| Industry Sector: Medical        | Email: support@zylon.com           |
| Devices                         |                                    |
+---------------------------------+------------------------------------+
| Zylon Corporation is located at |                                    |
| 600 Chestnut Ridge Rd.,         |                                    |
| Chestnut Ridge, NY 10977 in     |                                    |
| 2500 square feet of laboratory  |                                    |
| and office facilities. Core     |                                    |
| competency involves polymer     |                                    |
| science as applied to medical   |                                    |
| devices and clinical procedures |                                    |
| related to it. Zylon originally |                                    |
| was formed to provide expertise |                                    |
| related to polymers and medical |                                    |
| products made from polymers.    |                                    |
| Zylon has a current             |                                    |
| specialization in medical       |                                    |
| balloon catheters and related   |                                    |
| devices.                        |                                    |
+---------------------------------+------------------------------------+